Development Pipeline

Using aiProtein® technology, we design gain-of-function (GOF) enzymes to overcome the challenges of mRNA therapy, developing “GOF-enhanced mRNA therapeutics.” This approach is expected to be applicable to a wide range of inherited diseases as a new therapeutic modality.

As of Feburary, 2026

Project Indication Partner Lead Discovery PreClinical Clinical
Ph1 Ph2 Ph3
RKD001/003 Rare Disease
RKD002 Rare Disease
RKD004 Rare Disease Undisclosed

Research Presentation